Company / Cash & Equivalents
Bioventus Inc. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$51.2M
FY2025
5-year range
$30.2M / $51.2M
FY2021-FY2025
Trend
+23.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has increased for 3 consecutive years, from $30M in FY2022 to $51M in FY2025.
Based on SEC 10-K filings.
$51M in FY2025 with a 3-year CAGR of +19.3%.
Improved from $37M to $51M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +19.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Bioventus Inc.'s cash & equivalents has grown for 3 consecutive years.
- 3-year CAGR of +19.3%, indicating consistent growth.
- In FY2025, cash & equivalents increased 23.2% year-over-year.
- Lowest cash & equivalents in the period was in FY2022.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.93 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $51.2M | +23.2% |
| FY2024 | $41.6M | +12.5% |
| FY2023 | $37.0M | +22.5% |
| FY2022 | $30.2M | -31.3% |
| FY2021 | $43.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026